Industry groups lay legal groundwork against pricing demosnews2026-02-24T20:36:25+00:00February 24th, 2026|Endpoints News|
BioMarin fails to find buyer, pulls Roctavian gene therapy off marketnews2026-02-24T16:17:44+00:00February 24th, 2026|Endpoints News|
Immedica wins accelerated approval for once-rejected rare disease drugnews2026-02-24T14:18:23+00:00February 24th, 2026|Endpoints News|
Fortress to sell priority review voucher for $205Mnews2026-02-23T19:34:21+00:00February 23rd, 2026|Endpoints News|
FDA unveils long-awaited guidance on new pathway for individualized therapiesnews2026-02-23T16:30:45+00:00February 23rd, 2026|Endpoints News|
AbbVie budgets $380M for obesity and neuroscience API facilities in Chicagonews2026-02-23T16:00:44+00:00February 23rd, 2026|Endpoints News|
Frontier, Harbour do licensing deals with GSK, Solsticenews2026-02-23T15:03:25+00:00February 23rd, 2026|Endpoints News|
Vanda gets FDA approval for ‘franchise-extending’ antipsychoticnews2026-02-21T00:51:50+00:00February 21st, 2026|Endpoints News|
Ionis scraps Alzheimer’s drug for people with Down syndromenews2026-02-20T19:32:53+00:00February 20th, 2026|Endpoints News|
Supreme Court tariff ruling lets stand Trump’s authority to target pharma news2026-02-20T18:35:54+00:00February 20th, 2026|Endpoints News|
